Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2021-11-23 00:00:00 ET · period of report 2021-11-19 · accession 0001062993-21-011500 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-23 | 2021-11-19 | ENTA | MELLETT PAUL J | CFO, Treas | A - Grant | $0.00 | +6,800 | 56.6K | +14% | $0 |
| D | 2021-11-23 | 2021-11-19 | ENTA | MELLETT PAUL J | CFO, Treas | A - Grant | $0.00 | +28.4K | 28.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-19 | A | A | 6,800 | $0.00 | 56,559 | D | — | — | (F2) The amount of securities beneficially owned by the reporting person was incorrectly stated on the Form 4 filed on January 8, 2021 as "61,759" instead of "49,759." The amount of securities beneficially owned, as reported in column 5 of this Form 4, corrects this error. |
| 2 | Derivative | Stock Option (right to buy) | 2021-11-19 | A | A | 28,400 | $0.00 | 28,400 | D | $75.33 · — to 2031-11-19 | 28,400 Common Stock | (F3) Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021). |